Unmet needs in clinical research in breast cancer: Where do we need to go? by Partridge, A.H. & Carey, L.A.
UNMET NEEDS IN CLINICAL RESEARCH IN BREAST CANCER: 
Where do we need to go?
Ann H. Partridge, MD, MPH1 and Lisa A. Carey, MD2
1Dana-Farber Cancer Institute, Boston, MA, USA
2Lineberger Cancer Center, University of North Carolina, Chapel Hill, NC, USA
Abstract
This CCR Focus highlights areas in breast cancer research with the greatest potential for clinical 
and therapeutic application. The six articles in the issue address the state of the science in a broad 
range of areas with a focus on “hot” though sometimes controversial topics, unanswered 
questions, and unmet need. From mutational signatures, the cancer genomic revolution, and new 
inroads in immunotherapy for breast cancer, to unique concerns of vulnerable populations as well 
as national and global health disparities, these works represent much of the promise of breast 
cancer research as well as the challenges in the coming years. Each review focuses not only on 
recent discoveries, but also putting the topic in context including limitations to overcome. This 
overview is designed to further contextualize the highlighted issues within the broader research 
landscape. We also present new information from a poll of ALLIANCE for Clinical Trials in 
Oncology Breast Committee members regarding the most needed and viable potential future NCI-
supported clinical trials in breast cancer. The great challenge is to translate the potential benefits of 
greater scientific knowledge reflected in this Focus series into improvements in outcomes for 
individuals and populations with breast cancer. A unifying theme across the six articles contained 
in this CCR Focus is the increasingly recognized value and necessity of collaboration across 
disciplines from bench to bedside to populations. Only continued and iteratively amplified 
scientific, clinical and governmental commitment to creating, testing, and implementing new 
knowledge will reduce the global morbidity and mortality of breast cancer.
INTRODUCTION
Advances in early detection, prevention, risk stratification, and therapeutic strategies as well 
as supportive care for patients with breast cancer has resulted in important improvements in 
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morbidity and mortality. However, there are several areas where advances have not been 
fully actualized and substantial challenges remain. The challenges range from the need for a 
deeper understanding of cancer biology, inter- and intra-individual cancer heterogeneity, and 
inter-individual host biologic heterogeneity, to the challenges of conducting rigorous 
practice-changing prospective clinical trials tailored to biologically relevant subsets of the 
disease, and the need for governmental level prioritization and rational implementation of 
proven screening and therapeutic strategies to populations both in the U.S. and abroad 
(Figure 1). In this CCR Focus, we highlight select areas in breast cancer research, ranging 
from base pairs to population health and dissemination of life-saving interventions, that have 
emerged in recent years as having great promise but also have gaps in necessary knowledge 
to apply clinically. We also discuss recent efforts of the Breast Committee of the 
ALLIANCE for Clinical Trials in Oncology of the NCTN to identify highest priority 
research areas for future practice-changing cooperative group clinical trials.
OVERVIEW OF THIS CCR FOCUS
The genomics revolution has transformed the landscape of clinical research in cancer. 
Increased understanding of the biology of cancer, driver mutations as potential targets, and 
the mechanisms of sensitivity and resistance of breast cancer to conventional and newer 
targeted therapies has led to an explosion of studies seeking to translate laboratory findings 
to the clinic and address clinical challenges in the lab. In this CCR Focus issue, Nik-Zainal 
and Morganella begin at the base pair level and review recent work elucidating the potential 
for mutational scars to reflect a cancer’s pathogenesis, and also how this may translate into 
future therapeutic strategies.(1) They summarize the exciting though controversial area of 
mutational signatures in breast cancer based on their prior provocative work in this area.(2–
5) The focus on the history of the concept, work done to date, potential clinical application, 
and future promise tells a nice story. It should be noted that although data are intriguing, the 
extent to which this approach will help make sense of the genomic complexity of breast 
cancer remains uncertain. Specifically, whether mutational signatures represent the causative 
mechanism influenced by intensity and duration of exposure to specific mutational processes 
is unknown. And further, whether these will provide an actionable catalogue of mutations at 
the nucleotide level that portend outcome and targetability is intriguing but unclear.
Among the great success stories in translational ‘omics has been the impact of 
transcriptomic studies on our understanding of breast cancer biology. From the first 
description of the molecular portraits of breast cancer (6) that identified the now 
conventional biologic categories of “Luminal A”, “Luminal B”, “HER2-Enriched”, and 
“Basal-like”, to the elucidation that the Basal-like subtype is in fact a different disease entity 
from other breast cancer subtypes (7), we have an increasingly sophisticated view of the 
intrinsic subtypes within breast cancer. This has led to the development of multiple 
commercial and research RNA-based assays for predicting risk of recurrence and need for 
chemotherapy in hormone receptor-positive, HER2-negative early breast cancer, with two 
large prospective trials already demonstrating clinical utility of these assays in therapeutic 
decision-making. (8, 9) Current initiatives include efforts to use gene expression patterns of 
tumor and immune signatures to prognosticate and tailor treatment in HER2-positive (10–
12) and triple negative (13, 14) cancers. The landscape of translational transcriptomics was 
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recently reviewed in a CCR Anniversary commentary. (15) In this CCR Focus, Yates and 
Desmedt describe the current state of the science of DNA-based approaches and the 
challenges of the genomics revolution in how mutational and copy number aberrations relate 
to personalized medicine and breast cancer treatment. They highlight five major issues 
hampering our ability to harness the cancer genome to improve patient outcomes and 
elucidate not only the gaps, but potential steps to move forward.(16) In our view, the greatest 
obstacles for this work leading to improvements for patients with breast cancer include: a) 
the limited proportion of breast tumors found to have “actionable” mutations as currently 
defined, b) the need for integrative DNA- and RNA-based approaches, c) mixed results in 
terms of patient outcomes of molecularly-targeted approaches to date, d) within-patient 
tumor heterogeneity and challenges of obtaining optimal tumor testing at any given time, 
and e) the infrastructure and resource constraints that hamper our ability to implement such 
testing broadly to reach all patients. (17, 18)
Recent years have seen great successes in the long-studied but previously unyielding field of 
immunotherapy in cancer. We now know that tumor infiltrating lymphocytes and activated 
immune signatures in the tumor microenvironment independently affect prognosis and 
possibly response to therapy in triple negative and HER2-positive disease.(19) With a 
plethora of research and clinical trials of immune checkpoint and other immunotherapies 
emerging in breast cancer, we are at the beginning of a potential entirely new paradigm for 
breast cancer therapy; however at present the optimal means of leveraging the immune 
system across the biologic diversity of breast cancer remains elusive. Vonderheide and 
colleagues’ comprehensive review of current research and challenges of immunotherapy 
suggests how this may ultimately play into the treatment of patients with breast cancer.(20) 
Agents that have already yielded clinical improvements in the treatment of other, previously 
difficult-to-treat cancers are being tested in patients with breast cancer with hundreds of 
clinical trials ongoing or in development (www.clinicaltrials.org), and some promising 
results in early phase studies. (21–24) Tumor infiltrating lymphocytes and immune 
activation signatures are independently prognostic in triple negative and HER2-positive 
breast cancer supporting a potential role of immune-based strategies. (25) However, the 
burden of non-synonomous mutations is lower in breast cancer than in classically 
immunologically tractable cancers such as melanoma, and breaking immune tolerance 
appears to be more difficult. It is also likely that different molecular or phenotypic subtypes 
of breast cancer will derive varying benefit from the addition of immunotherapy to the 
armamentarium of therapy for patients with breast cancer and antigen unmasking, for 
example by DNA-damaging chemotherapy or radiation therapy, may have a potential role 
particularly in the breast tumors with lower mutational burdens (e.g luminal tumors). (26)
Clearly the interplay of tumor genomics and microenvironmental influences, complicates 
translation from bench to bedside when considering either efficacy in clinical trials or 
implementation in practice. In the era of the genomics revolution and development of 
multiple targeted therapies, this has become particularly complex (e.g. understanding and 
using tumor genomics to guide care) and resource intensive. Insights from social science 
suggest that these factors are likely to lead to an increase in disparities in access and 
outcomes in various populations both in the US and worldwide. The articles by Freedman 
and Partridge and Reeder-Hayes and Anderson focus on micro- and macro- population 
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issues that present challenges to actualizing and translating progress made beyond the 
traditional clinical trials setting.(27, 28) Of note, while these articles do not focus on 
biologic heterogeneity across populations, we do believe that this variable will continue to 
emerge as an important factor in breast cancer outcomes, and thus have included an arrow 
from population implementation and dissemination to biologic discovery and translational 
research in Figure 1. (29)
Freedman and Partridge discuss the recent advances in our understanding of issues facing 
special populations with breast cancer including age-related disparities, i.e. very young and 
very old patients; and concerns and management strategies when treating patients who are 
overweight or obese. Similarly, challenges exist for the minority of breast cancer patients 
who are men and have historically been treated extrapolating from datasets and clinical 
studies comprised predominantly of women.(27) Each of these special populations face 
challenges which this article highlights along with the exciting ongoing work in these 
vulnerable groups of patients to elucidate and overcome them to optimize care and 
outcomes. Notably, the review does not cover all vulnerable subpopulations with long-
standing or emerging recognition of unique medical and/or psychosocial concerns such as 
patients with substantial comorbidities, and LBGT individuals.
Reeder-Hayes and Anderson bring together two distinct areas of disparities: breast cancer 
disparities in the U.S., and global breast cancer disparities.(28) Their combined analysis 
conveys the importance of understanding the root causes of health outcomes disparities; 
understanding those root causes is key to overcoming them. In 1995, Link and Phelan 
published on the theory of fundamental causes to explain why the association between 
socioeconomic status (SES) and mortality persists despite radical improvement in our 
understanding of disease and explanatory risk factors. (30) Their proposal - that the enduring 
association is because SES embodies an array of resources such as money, knowledge, 
prestige, power, and beneficial social connections that affect health outcomes - appears to 
hold regardless of country as well. Thus, when considering disparities in outcomes across 
populations, while the issues within the U.S. are different from those elsewhere on the globe, 
especially from a legal, governmental, and cultural standpoint, the universal theme of 
resources and how they are utilized and prioritized in any system, emerges as of paramount 
importance regardless of setting.
The challenges and opportunities of the six topics covered in this Focus series highlight the 
importance of collaboration and stakeholder involvement in the design of effective and 
successful clinical research addressing gaps in knowledge. Clinical trials include novel 
therapeutic trials focused on improving efficacy, trials focused on comparative effectiveness 
of specific strategies, and risk stratification trials for tailored approaches. While all are 
worthy, some are suitable for large-scale practice-changing trials performed in the national 
cooperative group setting, and some may address research and knowledge gap questions 
raised in this Focus series.
In our roles as co-chairs of the ALLIANCE for Clinical Trials in Oncology Breast 
Committee of the National Cancer Institute’s National Clinical Trials Network (NCTN), we 
are mindful of the role of national cooperative groups in addressing clinically relevant 
Partridge and Carey Page 4













research. In November 2016, we surveyed the ALLIANCE Breast Committee membership, 
comprised of academic and community oncologists engaged in large scale clinical trials, 
regarding what they perceived to be key clinical questions as well as the feasibility of 
recruiting to trials addressing those questions. Fifty-seven responding committee members 
chose from among 11 broad research areas identified by ALLIANCE leadership. The 
findings of this survey have been analyzed descriptively and refined in order to identify the 
top ranking concepts (See Table 1). The gaps in knowledge identified by this survey by 
practicing clinicians illustrates the changing culture of breast cancer research, in which the 
multidisciplinary team including scientists, clinical and public health researchers, patient 
advocates, and clinicians are anxious to formally test biologic and health services advances. 
For example, the top-ranked priority was identifying patients at risk of late relapse using 
genomics, and testing novel endocrine therapy to prevent such late relapse in hormone 
receptor-positive early breast cancer. Transcriptomic assays show promise in this realm (31, 
32), which may be further aided by identifying relevant driver mutations in the primary as 
described in Focus article #2(16), although it should be noted that mature datasets with a 
high proportion of banked primary tissue that are large enough to address late relapse are 
rare, complicating design of trials to address this question. Next in priority was 
immunotherapy, the subject of Focus #3.(20) Most participating sites in the ALLIANCE 
have competing studies of these drugs, whose role is of high clinical and pharmaceutical 
interest. The NCTN is developing its first trial in this sphere, a large adjuvant immune 
checkpoint inhibitor trial in high-risk triple negative residual disease. Optimizing and 
developing intermediate biomarkers for outcome using pre-operative therapy for ER-positive 
breast cancer was also considered high priority. A currently accruing ALLIANCE study, 
ALTERNATE (NCT01953588), will test the clinical utility of an immunohistochemistry-
based prognostic score, the PEPI score (33). At this time, testing for clinical utility of 
mutational analyses of the type described in Focus articles #1 and #2 (1, 16) is premature, 
even though several other highly rated “unmet needs” involved genomic applications that 
may be informed by these sorts of mutational analyses, including optimizing treatment 
choices for hormone receptor-positive breast cancer, decision-making regarding need for 
radiation therapy, and identifying targetable aberrations in triple negative disease. As noted, 
RNA-based assays have begun to be studied in several of these realms, including guiding 
metastatic treatment in hormone receptor-positive disease (34), determining need for dual 
HER2-targeting and less aggressive regimens (10, 11), and tailoring radiation therapy to 
those at higher risk of locoregional failure. (35) Integrating and targeting DNA aberrations 
into such clinical problem-solving requires additional study but is clearly an opportunity. 
Several of the highest priority research gaps centered on improving delivery of care, 
including interventional studies to improve adherence to medication. This ranked highly in 
part because it is common, negatively impacts outcome, and in particular affects vulnerable 
breast cancer patients such as African-American (36–38) and women at both ends of the age 
spectrum. (36, 39–42). Comparative effectiveness, namely the comparison of existing 
approaches to determine greatest benefits and harms, was also felt to be an understudied 
topic, and one ripe for the cooperative group setting since these are difficult to fund studies 
outside of the federal sphere, and often have substantial public policy implications. Specific 
issues related to causes of nonadherence and the need for rigorous determination of best 
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therapies within and across populations are topics discussed in the FOCUS articles by 
Freedman and Reeder-Hayes.(27, 28)
Several unifying themes emerge from both the challenging topics of the Focus articles and 
the survey of research gaps in the clinic. First, advances in breast cancer outcomes cannot be 
achieved without attention to the heterogeneity of the disease. The molecular vernacular 
derived from RNA-based assays identifying Luminal A, Luminal B, basal-like and HER2-
Enriched have informed how we perceive breast cancer, and, increasingly, how we treat 
breast cancer.(6) Integrating the transcriptome, the genome (potentially including mutational 
signatures) and the tumor microenvironment with relevant clinical variables will be crucial 
to improving treatment options. Second, that comparative effectiveness research should be 
incorporated broadly into clinical research. It is as important to understand how well our 
treatment strategies work across populations and in various settings as it is to develop the 
strategy in the first place. Finally, the fundamental cause theory of disparities suggests that 
as we develop more effective treatment approaches and strategies, under-resourced 
individual patients with breast cancer, and diverse groups both in the US and abroad will be 
increasingly left behind. Unless we are proactive in identifying barriers to access and care, 
disparities will increase as progress is made.
SUMMARY
There is much work to be done and many challenges exist in our mission to end the suffering 
that breast cancer brings. Nevertheless, optimism prevails given the exciting work that has 
stemmed from global research collaborations and communications, recognition of the need 
for international clinical and translational trials, as well as an increasing attention to 
reducing disparities within and across populations. Knowledge gaps in each of these is 
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